Compare CFND & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFND | RLYB |
|---|---|---|
| Founded | N/A | 2018 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.4M | 28.7M |
| IPO Year | 2025 | 2021 |
| Metric | CFND | RLYB |
|---|---|---|
| Price | $3.85 | $10.83 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 35.2K | ★ 227.3K |
| Earning Date | N/A | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $600,000.00 |
| Revenue This Year | N/A | $17.61 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.68 | $0.22 |
| 52 Week High | $9.67 | $11.49 |
| Indicator | CFND | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 38.53 | 91.28 |
| Support Level | $3.82 | $0.48 |
| Resistance Level | $4.08 | N/A |
| Average True Range (ATR) | 0.15 | 0.87 |
| MACD | 0.02 | 0.47 |
| Stochastic Oscillator | 37.48 | 91.30 |
C1 Fund Inc is a non-diversified, closed-end management investment company designed to give investors access to the private digital asset ecosystem. Its investment objective is to maximize its portfolio's total return. The fund targets a handpicked portfolio of the late-stage private companies driving the future of digital asset services and technology. It offers early access to the next generation of category-defining companies and aims to bridge the gap between public and private markets and give investors access to the private companies with the safeguards of a NYSE listed fund that is regulated and liquid.
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.